Maximizing the benefits of thrombolytic therapy for acute myocardial infarction.

Published

Journal Article (Review)

Thrombolytic therapy is a huge advance in the management of acute myocardial infarction (AMI). The results of large clinical trials over the past 9 years have unequivocally demonstrated its benefit: of every 1000 patients treated 30 will be saved, at a cost of two cases of nonfatal cerebral hemorrhage and seven of noncerebral major hemorrhage. The concurrent use of acetylsalicylic acid increases the benefit of thrombolytic therapy. Sales figures for thrombolytic agents indicate that their use in Canada is less than optimal and lags behind that in several European countries. Major educational efforts are needed to promote awareness of the efficacy of thrombolytic therapy and of optimal approaches for maximizing its potential benefit for patients with AMI.

Full Text

Duke Authors

Cited Authors

  • Cairns, J; Armstrong, PW; Belenkie, I; Hirsh, J; Johnstone, DE; Knudtson, M; Lemieux, M; Massel, D; Naylor, CD; Roy, L

Published Date

  • March 15, 1995

Published In

Volume / Issue

  • 152 / 6

Start / End Page

  • 819 - 822

PubMed ID

  • 7697574

Pubmed Central ID

  • 7697574

International Standard Serial Number (ISSN)

  • 0820-3946

Language

  • eng

Conference Location

  • Canada